Three companies made significant purchases and product introductions in May and June in efforts to gain a larger share of the interventional, cath lab device market.

Combining IVUS, Therapeutic Devices

July 7, 2010 – Medical imaging company NovaRad recently expanded its distributor network by adding NXC Imaging to serve facilities in Wisconsin, South Dakota, North Dakota and parts of Illinois, Montana and Michigan.

NXC Imaging will represent NovaRad’s products including:

July 7, 2010 – Vicor Technologies Inc. recently announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its PD2i algorithm and software. This would secure a claim for identifying, in conjunction with patient medical history and other tests, congestive heart failure patients at elevated risk of cardiac mortality.

July 6, 2010 – Maquet Cardiovascular LLC recently announced it will become the exclusive U.S. distributor of the InterGard family of vascular grafts. This will go into effect on Oct. 1, 2010, when its current distribution agreement with W.L. Gore & Associates expires.

July 6, 2010 – A new trial testing a new method of detecting ischemia in patients with coronary artery disease (CAD) has received its first patient enrollments. Cambridge Heart Inc.

July 6, 2010 – The development of a new magnetic resonance imaging (MRI) technology, which may revolutionize the way medical conditions are diagnosed and treated, is to take a major step forward as a $10.6 million research center is established at the University of York.

July 6, 2010 – The government’s certification program for health information technology (HIT) will continue to evolve over time, according to a review of the recently released final rule for the temporary certification program, released last week.

July 6, 2010 – Ultrasound company SonoSite Inc. announced last week that it has completed its acquisition of privately held VisualSonics, a Toronto-based company focused on ultra high-frequency micro-ultrasound technology, for $67.9 million net of cash and debt.

July 1, 2010 – Two medical companies say they will work with physicians to further investigate ways to manage genetic issues in antiplatelet therapy, after the U.S. Food and Drug Administration (FDA) recently released a warning about the efficacy of the antiplatelet drug clopidogrel (Plavix) on patients with certain genetic make-ups.

July 1, 2010 – The U.S. Food and Drug Administration (FDA) recently added a warning to the information on clopidogrel (Plavix), as a result of new information indicating that variations in genetic makeup can prevent the medication from reducing patients’ risk for heart attack and stroke.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now